ABIONYX PHARMA SA (ABNX.PA) Fundamental Analysis & Valuation

EPA:ABNX • FR0012616852

Current stock price

3.54 EUR
-0.05 (-1.39%)
Last:

This ABNX.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ABNX.PA Profitability Analysis

1.1 Basic Checks

  • ABNX had negative earnings in the past year.
  • ABNX had a negative operating cash flow in the past year.
  • In the past 5 years ABNX always reported negative net income.
  • In the past 5 years ABNX always reported negative operating cash flow.
ABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -42.32%, ABNX is in line with its industry, outperforming 40.28% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -123.01%, ABNX is in line with its industry, outperforming 45.83% of the companies in the same industry.
Industry RankSector Rank
ROA -42.32%
ROE -123.01%
ROIC N/A
ROA(3y)-32.8%
ROA(5y)-30.33%
ROE(3y)-75.24%
ROE(5y)-67.78%
ROIC(3y)N/A
ROIC(5y)N/A
ABNX.PA Yearly ROA, ROE, ROICABNX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • ABNX has a worse Gross Margin (13.14%) than 61.11% of its industry peers.
  • ABNX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.77%
GM growth 5YN/A
ABNX.PA Yearly Profit, Operating, Gross MarginsABNX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ABNX.PA Health Analysis

2.1 Basic Checks

  • ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ABNX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ABNX has been increased compared to 5 years ago.
  • ABNX has a worse debt/assets ratio than last year.
ABNX.PA Yearly Shares OutstandingABNX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
ABNX.PA Yearly Total Debt VS Total AssetsABNX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • ABNX has an Altman-Z score of 7.45. This indicates that ABNX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.45, ABNX is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
  • A Debt/Equity ratio of 0.67 indicates that ABNX is somewhat dependend on debt financing.
  • ABNX has a Debt to Equity ratio (0.67) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Altman-Z 7.45
ROIC/WACCN/A
WACC7.93%
ABNX.PA Yearly LT Debt VS Equity VS FCFABNX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 1.06 indicates that ABNX should not have too much problems paying its short term obligations.
  • ABNX has a worse Current ratio (1.06) than 72.22% of its industry peers.
  • ABNX has a Quick Ratio of 1.01. This is a normal value and indicates that ABNX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.01, ABNX is doing worse than 69.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.01
ABNX.PA Yearly Current Assets VS Current LiabilitesABNX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ABNX.PA Growth Analysis

3.1 Past

  • The earnings per share for ABNX have decreased strongly by -22.25% in the last year.
  • Looking at the last year, ABNX shows a very negative growth in Revenue. The Revenue has decreased by -10.72% in the last year.
  • Measured over the past years, ABNX shows a decrease in Revenue. The Revenue has been decreasing by -8.20% on average per year.
EPS 1Y (TTM)-22.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.46%
Revenue 1Y (TTM)-10.72%
Revenue growth 3Y-8.2%
Revenue growth 5YN/A
Sales Q2Q%-11.92%

3.2 Future

  • Based on estimates for the next years, ABNX will show a very negative growth in Earnings Per Share. The EPS will decrease by -51.51% on average per year.
  • Based on estimates for the next years, ABNX will show a very strong growth in Revenue. The Revenue will grow by 102.89% on average per year.
EPS Next Y-97.83%
EPS Next 2Y-12.29%
EPS Next 3Y-51.51%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y78.82%
Revenue Next 3Y102.89%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABNX.PA Yearly Revenue VS EstimatesABNX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
ABNX.PA Yearly EPS VS EstimatesABNX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABNX.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ABNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABNX.PA Price Earnings VS Forward Price EarningsABNX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABNX.PA Per share dataABNX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • ABNX's earnings are expected to decrease with -51.51% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.29%
EPS Next 3Y-51.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABNX.PA Dividend Analysis

5.1 Amount

  • ABNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABNX.PA Fundamentals: All Metrics, Ratios and Statistics

ABIONYX PHARMA SA

EPA:ABNX (4/28/2026, 7:00:00 PM)

3.54

-0.05 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)N/A
Inst Owners4.48%
Inst Owner ChangeN/A
Ins Owners35.56%
Ins Owner ChangeN/A
Market Cap125.71M
Revenue(TTM)4.06M
Net Income(TTM)-5.55M
Analysts85
Price Target10.71 (202.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.94
P/FCF N/A
P/OCF N/A
P/B 27.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.11
BVpS0.13
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -42.32%
ROE -123.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.14%
FCFM N/A
ROA(3y)-32.8%
ROA(5y)-30.33%
ROE(3y)-75.24%
ROE(5y)-67.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.77%
GM growth 5YN/A
F-Score1
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 192.06%
Cap/Sales 5.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 1.01
Altman-Z 7.45
F-Score1
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)111.11%
Cap/Depr(5y)120.49%
Cap/Sales(3y)3.48%
Cap/Sales(5y)7.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.46%
EPS Next Y-97.83%
EPS Next 2Y-12.29%
EPS Next 3Y-51.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.72%
Revenue growth 3Y-8.2%
Revenue growth 5YN/A
Sales Q2Q%-11.92%
Revenue Next Year0%
Revenue Next 2Y78.82%
Revenue Next 3Y102.89%
Revenue Next 5YN/A
EBIT growth 1Y-24.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-82.52%
EBIT Next 3Y-54.52%
EBIT Next 5YN/A
FCF growth 1Y14.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.29%
OCF growth 3YN/A
OCF growth 5YN/A

ABIONYX PHARMA SA / ABNX.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ABIONYX PHARMA SA (ABNX.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ABNX.PA.


What is the valuation status for ABNX stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIONYX PHARMA SA (ABNX.PA). This can be considered as Overvalued.


How profitable is ABIONYX PHARMA SA (ABNX.PA) stock?

ABIONYX PHARMA SA (ABNX.PA) has a profitability rating of 1 / 10.


How financially healthy is ABIONYX PHARMA SA?

The financial health rating of ABIONYX PHARMA SA (ABNX.PA) is 3 / 10.